RGBPstock has lots of resistance to clear but company has show improvement or stock going sideway action
−0.0841 USD
−668.25 K USD
236.56 K USD
21.55 M
About Regen Biopharma, Inc.
Sector
Industry
CEO
David Raymond Koos
Website
Headquarters
La Mesa
Founded
2012
FIGI
BBG0072GHT40
Regen Biopharma, Inc. is a biotechnology company, which engages in the business of developing regenerative medical applications and advancing novel technologies through pre-clinical and Phase I and II clinical trials. It also focuses on mRNA and small molecule therapies for treating cancer and autoimmune disorders. The company was founded on April 24, 2012 and is headquartered in La Mesa, CA.
−790%
−630%
−470%
−310%
−150%
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
−480.00 K
−320.00 K
−160.00 K
0.00
160.00 K
Revenue
Net income
Net margin %
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
−480.00 K
−320.00 K
−160.00 K
0.00
160.00 K
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
−600.00 K
−400.00 K
−200.00 K
0.00
200.00 K
No news here
Looks like there's nothing to report right now
RGBP PHARMA PENNY STOCK RISING AFTER EARNINGSOTC:RGBP
RGBP just crossed over resistance, retested
and continued uptrend setting up for
long trade with stop loss below the horizontal
line.
Presently up 70% since 7/27 earnings
Crossing EMA Ribbon shows divergence /momentum
Considering a $5 Strike for Jan. '23
RGBP ( 0TC BIOTECH) Uptrend ContinuationOTC:RGBP
RGBP has gained 75% since earnings two weeks ago
and presently is in a pullback ripe for an entry.
Yesterday came the news of an application filing
with the USPTO, This should be a catalyst
for the resumption of the uptrend.
Technical Analysis - Price is sitting at the multisession
VWAP
$RGBP $RGBPP- Oversold Biotech Play Nearing Strong SupportSpecializing in the treatment of cancer and autoimmune diseases, Regen BioPharma Inc. (OTC: RGBP) and (OTC: RGBPP) is a biotech penny stock making notable contributions to the study and treatment of cancer. Currently focused on the development of its NR2F6 therapies, RGBP a an extensive portfolio of
$rgbp Chart Analysisupon review bullish divergence can be seen when combining rsi with price action
mac d is coming to retest
candles give off sign we''ve hit the bottom
huge buy of 30k today
descending triangle spotted that may break up or down
The Barchart Technical Opinion rating is a 72% Buy with a Weakest sh
RGBP CHART ANALYSISLong term indicators fully support a continuation of the trend.
Using RSI in combination with price action, bullish divergence had can be seen.
The 20sma has bullishly crossed the 200 sma
Maybe look for entries if a golden cross forms,
The golden cross is a technical chart pattern indicating the pot
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of RGBP is 0.0500 USD — it has decreased by −0.20% in the past 24 hours. Watch Regen Biopharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Regen Biopharma, Inc. stocks are traded under the ticker RGBP.
RGBP stock has fallen by −28.33% compared to the previous week, the last month showed zero change in price, over the last year Regen Biopharma, Inc. has showed a −85.51% decrease.
RGBP reached its all-time high on Sep 3, 2014 with the price of 750.0000 USD, and its all-time low was 0.0008 USD and was reached on Mar 12, 2020. View more price dynamics on RGBP chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
RGBP stock is 0.20% volatile and has beta coefficient of 0.66. Track Regen Biopharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Regen Biopharma, Inc. there?
Today Regen Biopharma, Inc. has the market capitalization of 1.08 M, it has decreased by −3.17% over the last week.
Yes, you can track Regen Biopharma, Inc. financials in yearly and quarterly reports right on TradingView.
RGBP net income for the last quarter is −460.81 K USD, while the quarter before that showed −270.75 K USD of net income which accounts for −70.20% change. Track more Regen Biopharma, Inc. financial stats to get the full picture.
No, RGBP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 16, 2025, the company has 1 employees. See our rating of the largest employees — is Regen Biopharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Regen Biopharma, Inc. EBITDA is −366.98 K USD, and current EBITDA margin is −176.37%. See more stats in Regen Biopharma, Inc. financial statements.
Like other stocks, RGBP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Regen Biopharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Regen Biopharma, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Regen Biopharma, Inc. stock shows the sell signal. See more of Regen Biopharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.